+

WO2001008670A3 - Methodes et compositions destinees a attenuer le begaiement - Google Patents

Methodes et compositions destinees a attenuer le begaiement Download PDF

Info

Publication number
WO2001008670A3
WO2001008670A3 PCT/US2000/020402 US0020402W WO0108670A3 WO 2001008670 A3 WO2001008670 A3 WO 2001008670A3 US 0020402 W US0020402 W US 0020402W WO 0108670 A3 WO0108670 A3 WO 0108670A3
Authority
WO
WIPO (PCT)
Prior art keywords
naphthyridin
chloro
diazepam
stuttering
oxohexyl
Prior art date
Application number
PCT/US2000/020402
Other languages
English (en)
Other versions
WO2001008670A2 (fr
Inventor
John J Murphy
Orlando Kay Jorgenson D
Original Assignee
Interneuron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interneuron Pharma filed Critical Interneuron Pharma
Priority to AU63810/00A priority Critical patent/AU6381000A/en
Publication of WO2001008670A2 publication Critical patent/WO2001008670A2/fr
Publication of WO2001008670A3 publication Critical patent/WO2001008670A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne des méthodes de traitement du bégaiement qui consistent à traiter les personnes concernées avec des modulateurs du récepteur de l'acide gamma-aminobutyrique (GABA). Des énantiomères actifs, des métabolites actifs et des sels pharmaceutiquement acceptables des modulateurs du récepteur de l'acide gamma-aminobutyrique, dont les cyclopyrrolones, sont des composants acceptables des compositions. Parmi les modulateurs de la classe des cyclopyrrolones figurent la pagoclone, la suriclone, la zopiclone, 2-(7-chloro-2-naphthyridin-1, 8-yl)-3-(5-méthyl-2-oxohexyl)isoindolin-1-one, 2-(7-chloro-2-naphthyridin-1,8-yl)isoindolin-1-yl-4-acétamidobutyrate, et 2-(7-chloro-1,8-naphthyridin-2yl)-3-(5-méthyl-5-hydroxy-2-oxohexyl)-1-isoindolinone.
PCT/US2000/020402 1999-07-29 2000-07-27 Methodes et compositions destinees a attenuer le begaiement WO2001008670A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63810/00A AU6381000A (en) 1999-07-29 2000-07-27 Methods and compositions for alleviating stuttering

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36269199A 1999-07-29 1999-07-29
US09/362,691 1999-07-29

Publications (2)

Publication Number Publication Date
WO2001008670A2 WO2001008670A2 (fr) 2001-02-08
WO2001008670A3 true WO2001008670A3 (fr) 2002-08-29

Family

ID=23427132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020402 WO2001008670A2 (fr) 1999-07-29 2000-07-27 Methodes et compositions destinees a attenuer le begaiement

Country Status (2)

Country Link
AU (1) AU6381000A (fr)
WO (1) WO2001008670A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU783516B2 (en) * 2001-04-30 2005-11-03 Warner-Lambert Company Methods, kits and compositions for using pyrrole derivatives
WO2003011255A1 (fr) 2001-07-04 2003-02-13 Sun Pharmaceutical Industries Limited Systeme d'administration regulee de medicament a retention gastrique
CA2786330C (fr) 2010-01-14 2013-11-19 Umecrine Mood Ab Composition pharmaceutique comprenant 3-beta-hydroxy-5-alpha-pregnan-20-one a proprietes de stockage et de solubilite ameliorees
WO2012109752A1 (fr) 2011-02-15 2012-08-23 Socpra Sciences Et Génie, S.E.C. Alcaloïdes stéroïdiens et leurs utilisations en tant qu'agents antimicrobiens contre les micro-organismes à défaut de transport d'électrons et en tant qu'exhausteurs d'agents microbiens contre des bactéries pathogènes
US9963445B2 (en) * 2013-08-05 2018-05-08 Syngenta Limited Chemical compounds
EP3579843A4 (fr) * 2017-02-10 2020-12-23 Asarina Pharma AB 3-bêta-hydroxy-5-alpha-prégnan-20-one destiné à être utilisé dans un traitement médical

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960779A (en) * 1986-12-02 1990-10-02 Rhone-Poulenc Sante Pyrrole derivatives, and pharmaceutical compositions which contain them and pharmacological methods of use
EP0398171A2 (fr) * 1989-05-19 1990-11-22 F. Hoffmann-La Roche Ag Utilisation des imidazodiazépines dans le traitement des symptômes neurologiques, associés aux troubles circulatoires du cerveau
WO1997011700A1 (fr) * 1995-09-29 1997-04-03 Eli Lilly And Company Methode de traitement d'un tic chronique
WO1999036064A2 (fr) * 1998-01-13 1999-07-22 Synchroneuron, Llc Methodes de traitement de la dyskinesie tardive et autres perturbations des mouvements

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960779A (en) * 1986-12-02 1990-10-02 Rhone-Poulenc Sante Pyrrole derivatives, and pharmaceutical compositions which contain them and pharmacological methods of use
EP0398171A2 (fr) * 1989-05-19 1990-11-22 F. Hoffmann-La Roche Ag Utilisation des imidazodiazépines dans le traitement des symptômes neurologiques, associés aux troubles circulatoires du cerveau
WO1997011700A1 (fr) * 1995-09-29 1997-04-03 Eli Lilly And Company Methode de traitement d'un tic chronique
WO1999036064A2 (fr) * 1998-01-13 1999-07-22 Synchroneuron, Llc Methodes de traitement de la dyskinesie tardive et autres perturbations des mouvements

Non-Patent Citations (44)

* Cited by examiner, † Cited by third party
Title
ALVES S.E. ET AL.: "Neonatal ACTH administration elicits long-term changes in forebrain monoamine innervation. Subsequent disruptions in hypothalamic-pituitary-adrenal and gonadal function", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 814, 1997, pages 226 - 251, XP001041117 *
AWAAD YASSER: "Tics in Tourette Syndrome: New treatment options.", JOURNAL OF CHILD NEUROLOGY, vol. 14, no. 5, May 1999 (1999-05-01), pages 316 - 319, XP008001766, ISSN: 0883-0738 *
BARATZ R. ET AL.: "Adult-onset stuttering treated with anticonvulsants", ARCHIVES OF NEUROLOGY, vol. 38, no. 2, 1981, pages 132, XP001033543 *
BASSETT M L ET AL: "AMELIORATION OF HEPATIC ENCEPHALOPATHY BY PHARMACOLOGIC ANTAGONISM OF THE GABA-A-BENZODIAZEPINE RECEPTOR COMPLEX IN A RABBIT MODEL OF FULMINANT HEPATIC FAILURE", GASTROENTEROLOGY, vol. 93, no. 5, 1987, pages 1069 - 1077, XP008001893, ISSN: 0016-5085 *
BELIAKOVA L. I.: "Effect of psycholeptics on several physiologic indices of stutterers", ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S.S. KORSAKOVA, vol. 76, no. 9, 1976, pages 1386 - 1391, XP001032536 *
BRADY J P: "THE PHARMACOLOGY OF STUTTERING A CRITICAL REVIEW", AMERICAN JOURNAL OF PSYCHIATRY, vol. 148, no. 10, 1991, pages 1309 - 1316, XP001033556, ISSN: 0002-953X *
BRADY J. P. ET AL.: "Alprazolam, citalopram, and clomipramine for stuttering", JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol. 20, no. 2, 2000, pages 287, XP008001773 *
CONCAS, A. ET AL: "The effect of cyclopyrrolones on GABAA receptor function is different from that of benzodiazepines", NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL. ( 1994 ), 350(3), 294-300, XP008001865 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, NADESON R ET AL: "Antinociceptive properties of propofol: Involvement of spinal cord gamma-aminobutyric acid-A receptors.", XP002197310, Database accession no. PREV199799791237 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; May 1999 (1999-05-01), BELELLI D ET AL: "The interaction of general anaesthetics and neurosteroids with GABAA and glycine receptors.", XP002196384, Database accession no. PREV199900355065 *
DI PAOLO T.: "Modulation of brain dopamine transmission by sex steroids", REVIEWS IN THE NEUROSCIENCES, vol. 5, no. 1, 1994, pages 27 - 41, XP001041114 *
DOBLE, A. ET AL: "RP 59037 and RP 60503: Anxiolytic cyclopyrrolone derivatives with low sedative potential. Interaction with the.gamma.-aminobutyric acidA/benzodiazepine receptor complex and behavioral effects in the rodent", J. PHARMACOL. EXP. THER. ( 1993 ), 266(3), 1213-26, XP008001867 *
DOBLE, A. ET AL: "RP 59037 and RP 60503: Anxiolytic cyclopyrrolone derivatives with low sedative potential. Interaction with the.gamma.-aminobutyric acidA/benzodiazepine receptor complex and behavioral effects in the rodent", J. PHARMACOL. EXP. THER. (1993), 266(3), 1213-26, XP008002651 *
DOBLE, A. ET AL: "The pharmacology of cyclopyrrolone derivatives acting at the GABAA /benzodiazepine receptor", ADV. BIOCHEM. PSYCHOPHARMACOL. ( 1992 ), 47(GABAERGIC SYNAPTIC TRANSM.), 407-18, XP008001864 *
EDGAR P F ET AL: "A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer's disease individuals.", MOLECULAR PSYCHIATRY, vol. 4, no. 2, March 1999 (1999-03-01), pages 173 - 178, XP008001894, ISSN: 1359-4184 *
EDGREN B ET AL: "A RESEARCH PROGRAM ON STUTTERING AND STRESS", ACTA OTO-LARYNGOLOGICA SUPPLEMENT, vol. 263., 1970, pages 113 - 118, XP008002570, ISSN: 0365-5237 *
EDGREN B ET AL: "A research programme on stuttering and stress.", ACTA OTO-LARYNGOLOGICA. SUPPLEMENT, (1969) 263 113-8., XP001033519 *
ELLIOTT R. L. ET AL.: "A case report of alprazolam-induced stuttering", JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol. 5, no. 3, 1985, pages 159 - 160, XP008001982 *
FUKAMI S ET AL: "THE EFFECTS OF A POINT MUTATION OF THE BETA2 SUBUNIT OF GABAA RECEPTOR ON DIRECT AND MODULATORY ACTIONS OF GENERAL ANESTHETICS", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 2/3, no. 368, 5 March 1999 (1999-03-05), pages 269 - 276, XP001066256, ISSN: 0014-2999 *
GENTILI E. ET AL.: "Therapeutic effects of a new psycholeptic agent (febarbamate, Solium) in pediatrics", MINERVA MEDICA, vol. 63, no. 18, 1972, pages 1058 - 1060, XP008002618 *
HEWLETT WILLIAM A: "The use of benzodiazepines in obsessive compulsive disorder and Tourette's syndrome.", PSYCHIATRIC ANNALS, vol. 23, no. 6, 1993, pages 309 - 316, XP008002601, ISSN: 0048-5713 *
HIGGINS G M ET AL: "GAMMA AMINOBUTYRIC ACID ANTAGONISM PRODUCED BY AN ORGANOPHOSPHATE-CONTAINING COMBUSTION PRODUCT", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 105, no. 1, 1990, pages 103 - 112, XP008001892, ISSN: 0041-008X *
HOMMERICH K W ET AL: "[Studies on the use of chlordiazepoxide (Librium) in the treatment of stuttering ]. Untersuchung über die Anwendung von Chlordiazepoxyd (Librium) in der Stottertherapie.", HNO, (1966 JUL) 14 (7) 211-8., XP001033559 *
HUANG J-H ET AL: "DEXTRO HYDRASTINE A POTENT COMPETITIVE ANTAGONIST AT MAMMALIAN GABA-A RECEPTORS", BRITISH JOURNAL OF PHARMACOLOGY, vol. 99, no. 4, 1990, pages 727 - 730, XP008001824, ISSN: 0007-1188 *
IM, HAESOOK K. ET AL: "Potentiation of.gamma.-aminobutyric acid-induced chloride currents by various benzodiazepine site agonists with the.alpha.1.gamma.2,.beta.2.gamma.2 and.alpha.1.beta.2.gamma.2 subtypes of cloned.gamma.-aminobutyric acid type A receptors", MOL. PHARMACOL. ( 1993 ), 44(4), 866-70, XP008001866 *
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 282, no. 3, 1997, pages 1181 - 1186, ISSN: 0022-3565 *
KARDOS J ET AL: "Synthesis, anti-GABA activity and preferred conformation of bicuculline and norbicuculline enantiomers", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 31, no. 10, 1996, pages 761 - 765, XP004070189, ISSN: 0223-5234 *
LAPIN I: "Phenibut (beta-Phenyl-GABA): A Tranquilizer and Nootropic Drug", CNS DRUG REVIEWS, vol. 7, no. 4, 2001, pages 471 - 481, XP008002627 *
LASTOVKA M: "Basic motor mechanisms in stuttering paroxysms", CASOPIS LEKARU CESKYCH, vol. 111, no. 6, 1972, pages 123 - 127, XP001033516 *
LASTOVKA: "Influence of some psychopharmaca on the increase of the amplitude of electrically induced monosynaptic spinal cord reflex during the paroxysm of stuttering.", FOLIA PHONIATRICA, KARGER, BASEL, CH, vol. 31, no. 1, 1979, pages 15 - 20, XP001033545 *
LEANDERSON R, ET AL.: "A new approach to the experimental study of stuttering and stress.", ACTA OTO-LARYNGOLOGICA, vol. Suppl 224, 1966, pages 311 - 316, XP001033504 *
LLOYD, G. K. ET AL: "The activity of zolpidem and other hypnotics within the.gamma.-aminobutyric acid ( GABAA ) receptor supramolecular complex, as determined by 35S-t-butylbicyclophosphorothionate (35S-TBPS) binding to rat cerebral cortex membranes", J. PHARMACOL. EXP. THER. ( 1990 ), 255(2), 690-6, XP008001863 *
MARCUS A. ET AL.: "Möglichkeiten medikamentöser Mitbehandlung des Stotterns im Kindes- und Jugendalter", ZEITSCHRIFT FUR KINDER- UND JUGENDPSYCHIATRIE, vol. 23, no. 3, 1995, pages 182 - 194, XP008002617 *
NEELANDS TORBEN R ET AL: "Spontaneous and gamma-aminobutyric acid (GABA)-activated GABAA receptor channels formed by epsilon subunit-containing isoforms.", MOLECULAR PHARMACOLOGY, vol. 55, no. 1, January 1999 (1999-01-01), pages 168 - 178, XP008001924, ISSN: 0026-895X *
NEUROCHEMISTRY INTERNATIONAL, vol. 34, no. 5, May 1999 (1999-05-01), pages 447 - 452, ISSN: 0197-0186 *
NISSANI M. ET AL.: "Stuttering caused by gabapentin", ANNALS OF INTERNAL MEDICINE, vol. 126, no. 5, 1997, pages 410, XP008001916 *
PETERSON, BRADLEY S. ET AL.: "A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette's syndrome", J. CLIN. PSYCHOPHARMACOL., vol. 18, no. 4, 1998, pages 324 - 331, XP001041113 *
RABUZZI D. D. ET AL.: "Spasmodic dysphonia: a clinical perspective", TRANSACTIONS - AMERICAN ACADEMY OF OPHTHALMOLOGY AND OTOLARYNGOLOGY, vol. 76, no. 3, 1972, pages 724 - 728, XP008001758 *
ROBERTS C J ET AL: "ACTION OF 7 CONVULSANTS AS ANTAGONISTS OF THE GAMMA AMINO BUTYRIC-ACID RESPONSE OF LIMULUS-POLYPHEMUS NEURONS", COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C COMPARATIVE PHARMACOLOGY, vol. 70, no. 1, 1981, pages 91 - 96, XP008001980, ISSN: 0306-4492 *
SCHOLZE, PETRA ET AL: "Affinity of various ligands for GABAA receptors containing.alpha.4.beta.3.gamma.2,.alpha.4.gamma.2, or.alpha.1.beta.3.gamma.2 subunits", EUR. J. PHARMACOL. ( 1996 ), 304(1-3), 155-162, XP001066258 *
SEDLÁCKOVÁ E: "A contribution to pharmacotherapy of stuttering and cluttering", FOLIA PHONIATRICA, vol. 22, no. 4, 1970, pages 354 - 375, XP008002619 *
SEILER N ET AL: "SYNERGISTIC ANTI CONVULSANT EFFECTS OF GAMMA-AMINO BUTYRIC-ACID TRANS AMINASE INHIBITORS AND GLYCINE", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 326, no. 1, 1984, pages 49 - 57, XP008001936, ISSN: 0028-1298 *
SIMMONDS M A: "CLASSIFICATION OF SOME GAMMA AMINO BUTYRIC-ACID ANTAGONISTS WITH REGARD TO SITE OF ACTION AND POTENCY IN SLICES OF RAT CUNEATE NUCLEUS", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 80, no. 4, 1982, pages 347 - 358, XP008001891, ISSN: 0014-2999 *
VASILENKO YU S ET AL: "Clinical characteristics of phonic spasm.", VESTNIK OTORINOLARINGOLOGII, no. 6, 1995, pages 45 - 49, XP008001765, ISSN: 0042-4668 *

Also Published As

Publication number Publication date
AU6381000A (en) 2001-02-19
WO2001008670A2 (fr) 2001-02-08

Similar Documents

Publication Publication Date Title
WO2001008670A3 (fr) Methodes et compositions destinees a attenuer le begaiement
Blobel et al. Studies on free and membrane-bound ribosomes in rat liver: I. Distribution as related to total cellular RNA
US4255316A (en) Ceramifiable silicone adhesives
WO1999033859A3 (fr) Nouveaux steroides anti-oestrogenes, compositions pharmaceutiques associees et leur mode d'utilisation
RU2002119587A (ru) Устройство для доставки лекарственных средств, обладающих антипрогестиновыми свойствами
WO2001085204A3 (fr) Procede et composition therapeutiques faisant appel a un complexe antigene-anticorps et a sa presentation par les cellules dendritiques
WO2003045330A3 (fr) Materiaux et procedes d'obtention de compositions de micelles
AR033042A1 (es) Terapia de reemplazo hormonal
Maguire et al. A decrease in neural sialyltransferase activity in Alzheimer’s disease
WO2000014205A3 (fr) Procedes pour produire des preparations de vecteurs aav recombinants de forte teneur depourvues de virus assistants
Weidenfeld et al. The function of the adrenocortical axis in permanent middle cerebral artery occlusion: effect of glucocorticoids on the neurological outcome
WO2006023496A3 (fr) Compositions de creme vaginale, kits correspondants et procedes d'utilisation
Sato et al. Apoptosis of cultured rat glomerular mesangial cells induced by IgG2a monoclonal anti-Thy-1 antibodies
AU2002303903A1 (en) Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions
AU3065299A (en) Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids
Leung et al. Differential gene expression of angiotensin II receptor subtypes in the epididymides of mature and immature rats
Tan et al. Oxidized low-density lipoprotein stimulates endothelin-1 release and mRNA expression from rat mesangial cells
Lopez et al. Impaired differentiation of Ig AB cell precursors in the Peyer's patches of protein depleted rats
Mallet et al. Primary cultured human thymic epithelial cells express both membrane-bound and soluble HLA-G translated products
Rakowicz-Szulczynska et al. Antagonistic effect of PDGF and NGF on transcription of ribosomal DNA and tumor cell proliferation
Sriraman et al. Evaluation of the role of FSH in regulation of Leydig cell function during different stages of its differentiation
Mircheff et al. Preparative scale isolation of basal-lateral plasma membranes from rat intestinal epithelial cells
Mulheron et al. Effects of Diethylstilbestrol on Rat Granulosa Cell and Thecal/Interstitial Cell Transforming Growth Factor-β2 mRNA Expression in Vivo: Analysis by Reverse Transcription-Polymerase Chain Reaction
AU7065101A (en) Method for preparing cold bituminous mixes and road pavements from bituminous emulsions, bituminous emulsions, cold bituminous mixes and road mats
Gupta et al. The effects of testosterone and progestins on the rate of β‐glucuronidase synthesis in mouse kidney as studied with an immunoprecipitation assay 1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载